Literature DB >> 17845546

Rimonabant as a novel therapeutic option for nonalcoholic steatohepatitis.

Matthias Banasch, Oliver Goetze, Wolfgang E Schmidt, Juris J Meier.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17845546     DOI: 10.1111/j.1478-3231.2007.01555.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


× No keyword cloud information.
  6 in total

1.  Treatment options for nonalcoholic Fatty liver disease.

Authors:  Shivakumar Chitturi
Journal:  Therap Adv Gastroenterol       Date:  2008-11       Impact factor: 4.409

Review 2.  Strategies to rescue steatotic livers before transplantation in clinical and experimental studies.

Authors:  Qiang Liu; Maria-Louisa Izamis; Hongzhi Xu; Tim Berendsen; Martin Yarmush; Korkut Uygun
Journal:  World J Gastroenterol       Date:  2013-08-07       Impact factor: 5.742

3.  The non-invasive (13)C-methionine breath test detects hepatic mitochondrial dysfunction as a marker of disease activity in non-alcoholic steatohepatitis.

Authors:  Matthias Banasch; M Ellrichmann; A Tannapfel; W E Schmidt; O Goetze
Journal:  Eur J Med Res       Date:  2011-06-21       Impact factor: 2.175

4.  Inhibiting CB1 receptors improves lipogenesis in an in vitro non-alcoholic fatty liver disease model.

Authors:  Dongmei Shi; Xi Zhan; Xiaofeng Yu; Minglei Jia; Ying Zhang; Jianfeng Yao; Xiaona Hu; Zhijun Bao
Journal:  Lipids Health Dis       Date:  2014-11-18       Impact factor: 3.876

Review 5.  Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists.

Authors:  Helen Butler; Márta Korbonits
Journal:  Eur J Endocrinol       Date:  2009-09-03       Impact factor: 6.664

Review 6.  Systematic review and meta-analysis on the adverse events of rimonabant treatment: considerations for its potential use in hepatology.

Authors:  Norberto C Chavez-Tapia; Felix I Tellez-Avila; Giorgio Bedogni; Lory S Crocè; Flora Masutti; Claudio Tiribelli
Journal:  BMC Gastroenterol       Date:  2009-10-09       Impact factor: 3.067

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.